Primary Tumor Response to Targeted Agents in Patients with Metastatic Renal Cell Carcinoma

被引:86
作者
Abel, E. Jason [2 ]
Culp, Stephen H.
Tannir, Nizar M. [3 ]
Matin, Surena F.
Tamboli, Pheroze [4 ]
Jonasch, Eric [3 ]
Wood, Christopher G. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Urol, Unit 1373, Houston, TX 77030 USA
[2] Univ Wisconsin, Dept Urol, Sch Med & Publ Hlth, Madison, WI USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA
关键词
Renal cell carcinoma; Metastatic; Targeted therapy; Presurgical therapy; Primary tumor response; INTERFERON-ALPHA; CYTOREDUCTIVE NEPHRECTOMY; CANCER; IMMUNOTHERAPY; BEVACIZUMAB; SUNITINIB; THERAPY; RECIST;
D O I
10.1016/j.eururo.2010.09.034
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: The recent development of multiple targeted agents for metastatic renal cell carcinoma (mRCC) has changed the treatment paradigm; hence the benefit and optimal timing of cytoreductive nephrectomy is being reevaluated. Objective: To determine primary tumor response to treatment with targeted agents in patients with mRCC. Design, setting, and participants: We reviewed the clinical and radiographic data of all mRCC patients seen at our institution between November 2004 and December 2009 without prior systemic treatment who received targeted therapy with their primary tumor in situ. Measurements: Two independent reviewers measured the diameter of primary and metastatic tumors at baseline and subsequent scans, using Response Evaluation Criteria Solid Tumors (RECIST) v.1.1 to assess disease response. Results and limitations: We identified 168 consecutive patients with a median 15 mo of follow-up and a median maximum tumor diameter of 9.6 cm. Median maximum primary tumor response was -7.1% (interquartile range: -14.0 to -0.1). A total of 61 patients had multiple studies available for evaluation. In 43 patients with <10% decrease in primary tumor within in the first 60 d, median maximum response was -7.2% at 154 d versus -24.5% maximum response at 174.5 d for 18 patients with >= 10% decrease in primary tumor during the initial 60 d. Conclusions: Decrease in primary tumor diameter >30% while on targeted therapy for mRCC is rare, with most patients demonstrating minimal or no decrease in primary tumor diameter. Early response predicts a better overall primary tumor response. (C) 2010 European Association of Urology. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:10 / 15
页数:6
相关论文
共 50 条
  • [31] Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis
    Buchler, Tomas
    Bortlicek, Zbynek
    Poprach, Alexandr
    Pavlik, Tomas
    Veskrnova, Veronika
    Honzirkova, Michaela
    Zemanova, Milada
    Fiala, Ondrej
    Kubackova, Katerina
    Slaby, Ondrej
    Svoboda, Marek
    Vyzula, Rostislav
    Dusek, Ladislav
    Melichar, Bohuslav
    EUROPEAN UROLOGY, 2016, 70 (03) : 469 - 475
  • [32] A Comprehensive Overview of Targeted Therapy in Metastatic Renal Cell Carcinoma
    Mihaly, Z.
    Sztupinszki, Z.
    Surowiak, P.
    Gyorffy, B.
    CURRENT CANCER DRUG TARGETS, 2012, 12 (07) : 857 - 872
  • [33] Management of metastatic renal cell carcinoma in the era of targeted therapies
    Webber, K.
    Cooper, A.
    Kleiven, H.
    Yip, D.
    Goldstein, D.
    INTERNAL MEDICINE JOURNAL, 2011, 41 (08) : 594 - 605
  • [34] Patients with metastatic renal cell carcinoma who receive immune-targeted therapy may derive survival benefit from nephrectomy
    Dong, Hanzhi
    Cao, Yuan
    Jian, Yan
    Lei, Jun
    Zhou, Weimin
    Yu, Xiaoling
    Zhang, Xiquan
    Peng, Zhiqiang
    Sun, Zhe
    BMC CANCER, 2023, 23 (01)
  • [35] Role of enhancement modifications in evaluating tumor response to immunotherapy in metastatic renal cell carcinoma
    Dionese, Michele
    Pierantoni, Francesco
    Bezzon, Elisabetta
    Cumerlato, Enrico
    Bimbatti, Davide
    Basso, Umberto
    Maruzzo, Marco
    Zagonel, Vittorina
    TUMORI JOURNAL, 2023, 109 (06): : 562 - 569
  • [36] Vascularity of primary and metastatic renal cell carcinoma specimens
    Aziz, Saadia A.
    Sznol, Joshua
    Adeniran, Adebowale
    Colberg, John W.
    Camp, Robert L.
    Kluger, Harriet M.
    JOURNAL OF TRANSLATIONAL MEDICINE, 2013, 11
  • [37] VEGF Expression and Response to Sunitinib in Patients with Metastatic Clear Cell Renal Cell Carcinoma
    Minardi, Daniele
    Lucarini, Guendalina
    Santoni, Matteo
    Mazzucchelli, Roberta
    Burattini, Luciano
    Pistelli, Mirco
    Bianconi, Maristella
    Di Primio, Roberto
    Scartozzi, Mario
    Montironi, Rodolfo
    Cascinu, Stefano
    Muzzonigro, Giovanni
    ANTICANCER RESEARCH, 2013, 33 (11) : 5017 - 5022
  • [38] Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma
    Benedict, Agnes
    Figlin, Robert A.
    Sandstrom, Per
    Harmenberg, Ulrika
    Ullen, Anders
    Charbonneau, Claudie
    Sandin, Rickard
    Remak, Edit
    Hariharan, Subramanian
    Negrier, Sylvie
    BJU INTERNATIONAL, 2011, 108 (05) : 665 - 672
  • [39] Alternate sunitinib schedules in patients with metastatic renal cell carcinoma
    Kalra, S.
    Rini, B. I.
    Jonasch, E.
    ANNALS OF ONCOLOGY, 2015, 26 (07) : 1300 - 1304
  • [40] Response to post-axitinib treatment in patients with metastatic renal cell carcinoma
    Chittoria, Namita
    Haddad, Housam
    Elson, Paul
    Tannir, Nizar M.
    Wood, Laura S.
    Dreicer, Robert
    Garcia, Jorge A.
    Rini, Brian I.
    Jonasch, Eric
    BMC CANCER, 2016, 16